A study published on Monday, July 8, 2024, has revealed compelling findings regarding the effectiveness of tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) in weight loss management.
Researchers from Truveta Inc., led by Dr. Nicholas Stucky, vice president of research, reported in the journal JAMA Internal Medicine that individuals with overweight or obesity treated with tirzepatide experienced significantly greater weight loss compared to those treated with semaglutide. The study tracked over 18,000 participants prescribed either drug between May 2022 and September 2023.
Originally developed as medications for type 2 diabetes, both tirzepatide and semaglutide have gained approval for aiding weight loss. The study found that nearly 82% of patients on Mounjaro lost 5% or more of their body weight, whereas about 67% of those on Ozempic achieved similar results.
The disparity was even more pronounced in higher weight loss categories: approximately 42% of Mounjaro users lost 15% or more of their body weight, compared to only 18% of Ozempic users. Overall, patients on Mounjaro were 76% more likely to lose 5% or more of their body weight, 2.5 times more likely to lose 10% or more, and 3.2 times more likely to lose 15% or more, compared to those on Ozempic.
Throughout the first year of treatment, Mounjaro users consistently showed greater reductions in body weight compared to Ozempic users. After three months, Mounjaro patients had lost about 6% of their body weight versus under 4% for Ozempic patients. This trend continued with Mounjaro patients achieving a 10% reduction versus 6% at six months, and 15% versus 8% at one year.
Both drugs operate by mimicking the action of the gut hormone GLP-1, which helps stabilize blood sugar levels, slows digestion, and enhances feelings of fullness. However, Mounjaro uniquely stimulates another gut hormone called GIP, which likely contributes to its enhanced weight loss effects observed in the study.
These findings highlight significant advancements in weight management therapies and underscore the potential benefits of tirzepatide over semaglutide for individuals seeking effective solutions for weight loss.
Source: JAMA Internal Medicine, news release, July 8, 2024
**Disclaimer:** Statistical data presented in medical studies reflect general trends and may vary for individual cases. Personalized medical advice is recommended for specific healthcare decisions.